CEL-SCI, FDA Agree on Phase 3 Trial Design for Cancer Drug

Seeking Alpha11/08 00:31

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Businesswire11/07 21:15

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...

Benzinga10/22 21:26

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Businesswire10/22 21:15

CEL-SCI Selects Ergomed as CRO as It Gears Up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer

Businesswire10/01 18:00

CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to Be in the Treatment Group for Surgery and Radiation

Businesswire09/16 19:30